High prevalence of occult hepatitis C infection in predialysis patients

doi:10.4254/wjh.v11.i1.109

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 11, Issue 1

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5854)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-2) series.

Item

Count

PDF

306

WORD

257

HTML

2470

Figures (1-1)

258

Tables (1-2)

247

Sum=3538

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

839

Download

1477

Sum=2316

Jan 27, 2019 (publication date) through Feb 5, 2025

Times Cited of This Article

Times Cited (4)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

World J Hepatol. Jan 27, 2019; 11(1): 109-118
Published online Jan 27, 2019. doi: 10.4254/wjh.v11.i1.109

Table 1 Distribution of clinical parameters according to the occurrence of occult hepatitis C virus infection in 91 patients with chronic kidney disease: 2015 to 2017

	Total (%), n = 91	Occult hepatitis C infection		P-value
	Total (%), n = 91	Yes (%), n = 15	No (%), n = 76	P-value
Age	62.4 ± 13.1	69.4 ± 7.9	60.9 ± 13.5	0.002¹
Age ≥ 60 yr				0.001¹
Yes	59 (64.8)	15 (100)	44 (57.9)
No	32 (35.2)	0 (0)	32-42.1
Sex				0.323²
Male	44 (48.4)	9 (60)	35 (46.1)
Female	47 (51.6)	6 (40)	41 (53.9)
Ethnicity				0.719¹
Mixed	50 (54.9)	7 (46.7)	43 (56.6)
Caucasian	30 (33.0)	6 (40.0)	24 (31.6)
African Americans	11 (12.1)	2 (13.3)	9 (11.8)
BMI	27.1 ± 4.4	27.4 ± 4.7	27.0 ± 4.3	0.750¹
GFR	21.6 ± 10.3	24.6 ± 10.6	21.0 ± 10.2	0.231¹
CKD stage				0.580²
IIIa	2 (2.2)	0 (0)	2 (2.7)
IIIb	22 (24.4)	6 (40.0)	16 (21.3)
IV	38 (42.2)	5 (33.3)	33 (44.0)
V	28 (31.1)	4 (26.7)	24 (32.0)
Etiology of CKD				0.019²
Mixed	31 (34.1)	11 (73.3)	20 (26.3)
DM	26 (28.6)	1 (6.70)	25 (32.9)
HA	19 (20.9)	3 (20.0)	16 (21.1)
ADPKD	7 (7.70)	0 (0)	7 (9.20)
Others	1 (1.1)	0 (0)	1 (1.3)
ALT^e	18.1 (14.2; 23.2)	17.9 (15.2; 20.9)	18.1 (14.2; 24.7)	0.859
AST^e	19.5 (16.6; 24.8)	18.1 (17; 22.6)	19.5 (16.6; 25.3)	0.713

¹Student’s t test;

²Fisher’s exact test;. ADPKD: Autosomal dominant polycystic kidney disease; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; BMI: Body mass index; CKD: Chronic kidney disease; DM: Diabetes mellitus; GFR: Glomerular filtration rate; HA: Hypertension.

Table 2 Distribution of antibodies against hepatitis B virus according to the occurrence of hepatitis C virus occult infection in 89 patients with chronic kidney disease: 2015 to 2017

	Total (%), n = 89	Occult HCV infection		P-value
	Total (%), n = 89	Yes (%), n = 14	No (%), n = 75	P-value
Anti-HBs + anti-HBc total
Positive	13 (14.6)	7 - 50	6 - 8	0.001¹
Anti-HBs (anti-HBc negative)
Positive	31 (34.8)	4 (28.6)	27 - 36	0.590¹
Anti-HBs + anti-HBc total
Negative	45 (50.6)	3 (21.4)	42 - 56	0.01¹

¹Fisher’s exact test. HBc: Hepatitis B core protein; HBs: Hepatitis B surface protein; HBV: Hepatitis B virus; HCV: Hepatitis C virus.

Citation: Sette LHBC, Lopes EPA, Guedes dos Anjos NC, Valente LM, Vieira de Oliveira SA, Lucena-Silva N. High prevalence of occult hepatitis C infection in predialysis patients. World J Hepatol 2019; 11(1): 109-118
URL: https://www.wjgnet.com/1948-5182/full/v11/i1/109.htm
DOI: https://dx.doi.org/10.4254/wjh.v11.i1.109